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INTRODUCTION
Modern drug discovery techniques result in the develop-
ment of an increasing number of highly lipophilic drug
candidates. Their lipophilicity results in a slow dissolution
of these drugs in the aqueous gastro-intestinal fluids,
resulting in a poor bioavailability. Over the past few
decades, many strategies have been developed to increase
the dissolution rate of these types of drugs. The application
of drug nanocrystals is one technique. The dissolution rate
of drugs from nanocrystals is increased due to an increase of
the saturation concentration around these particles (Kelvin
law) and an increase of the surface area available for
dissolution.
Preparation techniques for drug nanocrystals can be
divided into top-down and bottom-up techniques. Top-
down techniques are based on size reduction of
relatively large particles into smaller particles, whereas
bottom-up techniques consist of the growth of small
particles from individual molecules. The driving force
for the growth of a crystal from individual molecules is
supersaturation. Supersaturation of a drug in a solution
can be obtained by decreasing the temperature or
addition of an anti-solvent.
The size of crystals formed from supersaturated pure
drug solutions depends on the balance between the
nucleation rate and crystal growth. This balance between
nucleation and growth is determined by the extent of
supersaturation. At a higher extent of supersaturation, the
nucleation rate increases, and, hence, the crystal size
decreases, whereas at a lower extent of supersaturation,
the growth rate increases, and, hence, the crystal size
increases. Therefore, process conditions, such as tempera-
ture or the ratio between solvent and anti-solvent and their
mixing rate, can be used to control the drug crystal size.
When drug crystals are formed in drug composites, the size
of the crystals is also determined by the interstitial spaces
between matrix molecules.
While there are many excellent reviews on top-down
techniques (e.g. (1,2)), bottom-up techniques are usually just
referred to as “precipitation techniques.” Bottom-up tech-
niques can be considered as the oldest techniques to
prepare drug nanocrystals. However, recently, interesting
new developments in the field of bottom-up preparation of
drug nanocrystals have evolved. This commentary focuses
on these techniques. First, an overview of bottom-up
preparation techniques of crystalline drug nanoparticles
will be given (Table I). Second, the process-related barriers
for products prepared by these techniques to reach the
market will be discussed. For an introduction on top-down
methods to prepare drug nanocrystals and the application
thereof, the reader is referred to an excellent recently
published review (2).
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Since bottom-up techniques to prepare drug nanocrystals
are commonly referred to as “precipitation methods,” solid
dispersions are usually not considered to be the first product
containing drug nanocrystals. However, some types of solid
dispersions consist of nanocrystalline drug particles embed-
ded in a matrix. Already in the early 1960s, Sekiguchi et al.
prepared a solid dispersion of the poorly soluble sulfathia-
zole embedded in urea (3). The small particles were
prepared by melting the drug and matrix and subsequently
cooling this mixture in an ice bath. This resulted in a
carrier matrix with drug particles entrapped in it. The size
of the nanoparticles could be controlled by process
parameters such as the cooling rate.
A little later, Tachibani et al. developed the solvent
evaporation method to prepare solid dispersions (4). To
obtain a solid dispersion by this method, the drug and
matrix are dissolved in a common solvent (e.g. chloroform),
after which the solvent is evaporated under vacuum. When
Tachibani developed this method, the drug was incorpo-
rated in the matrix monomolecularly or as amorphous
nanoparticles. Although this can be a successful strategy to
increase the dissolution rate, there are concerns regarding
the physical stability of these solid dispersions. Since
amorphous solid dispersions have the risk of uncontrolled
crystallization during processing or storage, a crystalline
product is usually preferred. After the solvent evaporation
method was adjusted, it could be used to prepare nano-
crystalline solid dispersions by this method as well (5).
The first traditional precipitation technique that has
been developed is the so-called hydrosol technique,
invented by List and Sucker (6). To obtain drug nano-
crystals by this technique, the lipophilic drug is first
dissolved in an organic solvent (e.g. ethanol) and then
mixed with a large amount of anti-solvent that is miscible
with the organic solvent, usually water. Mixing of the
organic solution and the anti-solvent should be performed
rapidly to assure fast nucleation and thereby small particles.
To stabilize the nanocrystals, a carrier (e.g. gelatin) can be
dissolved in the aqueous phase. Hereafter, the solvents can
then be removed by evaporation or lyophilization to obtain
a dry nanocrystalline drug product.
Another category of bottom-up techniques that was
developed is commonly known as supercritical fluid
technologies. Although there are currently many different
processes to prepare drug nanocrystals based on supercrit-
ical fluid technologies, they are all more or less based on gas
anti-solvent recrystallization (GAS) and rapid expansion of
supercritical solutions (RESS). The application of GAS to
obtain drug nanocrystals was for the first time described in
1991 by Krukonis et al.( 7). In this process, the supercritical
fluid acts as an anti-solvent. A solution of the lipophilic drug
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Bottom-Up Preparation Techniques for Nanocrystals 1221in an organic solvent is saturated with supercritical fluid
(such as supercritical CO2), thereby decreasing the solubil-
ity of the drug in the solvent and consequently causing the
drug to precipitate. The other supercritical fluid technique,
RESS, was already widely described in other applications
before it was for the first time described in 1999 by Pace et
al. to prepare drug nanocrystals (8). In this process, the
supercritical fluid acts as a solvent. The lipophilic drug is
dissolved in the supercritical fluid, after which the pressure
is rapidly decreased. Due to the decrease of solvent power,
the drug rapidly precipitates from the supercritical fluid.
More recently, a freeze-drying technique to prepare
drug nanocrystals, controlled crystallization during freeze-
drying (CCDF), was developed (9). This technology is based
on freeze-drying a mixture of a non-toxic organic solvent
(tertiary butyl alcohol) in which the drug is dissolved and an
aqueous solution containing a matrix material (e.g. manni-
tol). Freeze-drying is performed at a relatively high
temperature (above the glass transition temperature of the
maximally freeze-concentrated fraction) to allow the drug
and matrix to crystallize.
In the future, other bottom-up techniques to prepare
drug nanocrystals based on existing processes may be
developed. Bottom-up techniques, such as spray-freezing
into liquid (10) or nanoprecipitation in microfluidic reactors
(11), are promising techniques to prepare drug nano-
crystals. Currently, they are used to prepare amorphous
nanoparticles, but they may be adapted in such a way that
they can be used to produce a nanocrystalline drug
product. Spray-freezing into liquid (SFL), for example,
consists of similar process steps as CCDF. A mixture of
drug, polymer, organic solvent, and water is rapidly frozen
and then freeze-dried. Although there are more differences
between these two processes, the most important difference
is that the solutions used during SFL are, at least at room
temperature, thermodynamically stable, while the mixture
used during CCDF is not. So far, SFL is only reported to
yield amorphous nanoparticles, but when process condi-
tions, such as the concentration organic solvent or the
freeze-drying temperature are modified, crystalline nano-
particles may be obtained.
BOTTOM-UP PREPARED NANOCRYSTALS
ON THE MARKET
Whereas there are already several nanocrystalline products
on the market prepared by top-down methods (2), the
number of products prepared by bottom-up methods is
very limited. Rare examples are products such as Gris-
PEG
® (griseofulvin in PEG8000) and Cesamet
® (nabilone
in PVP). The few bottom-up prepared nanocrystalline
products are still based on the solid dispersion technology
as described by Sekiguchi and Obi, which dates back
almost fifty years ago. Although there are many promising
in-vitro results published, only a few of these efforts resulted
in a marketed product.
It is therefore worthwhile to analyze why there are so
few nanocrystalline drug products based on bottom-up
preparation techniques. Commonly mentioned disadvan-
tages of these techniques are possible decomposition of the
drug (hot melt method), contamination from toxic organic
solvents (solvent evaporation method), difficulty controlling
the size of the drug crystals (hydrosol), limited solubility of
the drug in the solvent (supercritical fluid technologies), and
long processing times (CCDF). However, top-down meth-
ods also suffer from disadvantages such as contamination
from grinding media, difficulty achieving a uniform size
distribution, and long processing times. These disadvan-
tages did not limit the development of commercialized
nanocrystalline drug products based on top-down prepara-
tion techniques.
Therefore, it seems to be unlikely that the above-
mentioned disadvantages are the most important reasons
that only a limited number of bottom-up prepared nano-
crystalline drug products reached the market. A more
plausible explanation may be the difficulty to scale-up the
bottom-up processes. For obvious reasons, most bottom-
preparation methods are developed on lab-scale. However,
to utilize these potentially useful bottom-up techniques, one
should think about industrial production. This means that
for each technique the possibility to change the process into
a continuous and/or large scale process should be kept in
mind. Also, the use of toxic organic solvents should be
minimized to reduce the risks during manufacturing and
the risk of high concentrations of residual impurities in the
end product.
Large-scale production of drug nanocrystals by bottom-
up techniques is not necessarily problematic. Techniques
such as the hot melt method, some supercritical fluid
methods, and CCDF seem to be suitable for scale-up. For
example, the lab-scale hot melt method can be changed
into a large-scale holt melt extrusion process, and freeze-
drying during CCDF can be changed into continuous spray
freeze-drying. However, more research should be per-
formed on the actual feasibility of these techniques to be
used for large-scale production, before they can be seen as
an alternative to the currently used top-down methods.
In conclusion, although there are only a limited number of
products based on bottom-up preparation of drug nano-
crystals on the market, promising technologies are available.
Examples of these techniquesa r eh o tm e l te x t r u s i o n ,
supercritical fluid technologies, and CCDF. However,
products prepared by these or other bottom-up techniques
will only reach the market if the industrial production is
already kept in mind during lab-scale development.
1222 Waard, Frijlink and HinrichsOpen Access This article is distributed under the terms of
the Creative Commons Attribution Noncommercial Li-
cense which permits any noncommercial use, distribution,
and reproduction in any medium, provided the original
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